593 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Acadian Asset Management LLC

Acadian Asset Management LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, Holdings Channel reports. The firm bought 593 shares of the biopharmaceutical company’s stock, valued at approximately $112,000.

Several other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after purchasing an additional 126,373 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.7% in the 1st quarter. BlackRock Inc. now owns 8,548,962 shares of the biopharmaceutical company’s stock worth $1,712,528,000 after buying an additional 59,582 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock valued at $761,144,000 after purchasing an additional 10,609 shares during the period. State Street Corp increased its position in shares of Alnylam Pharmaceuticals by 2.1% during the 1st quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock valued at $475,091,000 after purchasing an additional 59,101 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 2.9% in the 1st quarter. Geode Capital Management LLC now owns 1,738,115 shares of the biopharmaceutical company’s stock worth $347,684,000 after purchasing an additional 48,186 shares during the period. 93.98% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $165.26 on Tuesday. The firm’s fifty day moving average is $170.13 and its two-hundred day moving average is $185.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $148.10 and a 52-week high of $242.97. The company has a market cap of $20.74 billion, a P/E ratio of -39.92 and a beta of 0.47.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALNY. BMO Capital Markets cut their target price on shares of Alnylam Pharmaceuticals from $250.00 to $234.00 and set an “outperform” rating for the company in a research report on Tuesday, October 10th. Royal Bank of Canada decreased their target price on Alnylam Pharmaceuticals from $235.00 to $230.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus reiterated a “buy” rating and set a $240.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 14th. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $237.00 to $218.00 in a research report on Tuesday, October 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 25th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $233.00.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.